An Open-Label, Multi-Center, Phase 2 Dose Ranging Study of BRM424 Ophthalmic Solution in Patients With Neurotrophic Keratitis (NK)

Inclusion Criteria: * Be at least 18 years of age; * Provide written informed consent; * Patients with NK Stage 2 (PED) or Stage 3 (corneal ulcer); Exclusion Criteria: * Any active ocular infection (bacterial, viral, fungal or protozoal) or active ocular inflammation not related to NK; * Anticipated need to use therapeutic contact lenses or contact lens wear for refractive correction during the 28-days Treatment Period in the eye(s) with NK; * Be a woman of childbearing potential who is not using an acceptable means of birth control;